Establishment Labs Announces Complete Enrollment in Motiva US IDE Study
Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving womens health and wellness, principally in breast aesthetics and reconstruction, today announced it has completed enrollment in the Motiva US IDE clinical study.
- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving womens health and wellness, principally in breast aesthetics and reconstruction, today announced it has completed enrollment in the Motiva US IDE clinical study.
- The Augmentation cohort, which finished enrollment in August of 2019, will complete its third year of study follow-up this month.
- The Motiva US IDE study enrolled 827 patients at 32 centers in the US, Germany, and Sweden.
- Having completed full enrollment in the IDE study across all patient groups, we are diligently working with the plastic surgeons in the trial to maintain high patient follow-up, said Juan Jos Chacn-Quirs, Founder and CEO of Establishment Labs.